Personalis

OverviewSuggest Edit

Personalis operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. 

TypePublic
Founded2011
HQMenlo Park, CA, USMap
Websitepersonalis.com
Employee Ratings3.8More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2019)147
Revenue (FY, 2019)$65.2 M(+73%)
Share Price (Jan 2021)$51 (+5%)
Cybersecurity ratingBMore

Key People/Management at Personalis

John West

John West

Chief Executive Officer, Board Member
Richard Chen

Richard Chen

Chief Science Officer
Aaron Tachibana

Aaron Tachibana

Chief Financial Officer
Carol J. Tillis

Carol J. Tillis

Vice President, Finance and Administration
Stephen Moore

Stephen Moore

General Counsel
Christian Haudenschild

Christian Haudenschild

Vice President, Genomic Services
Show more

Personalis Office Locations

Personalis has offices in Menlo Park and West Wickham
Menlo Park, CA, US (HQ)
1330 O'Brien Dr
West Wickham, GB
Squires House, 205A High Street
Show all (2)

Personalis Financials and Metrics

Personalis Revenue

Embed Graph
View revenue for all periods
Personalis's revenue was reported to be $65.21 m in FY, 2019
USD

Revenue (Q3, 2020)

19.8m

Gross profit (Q3, 2020)

5.3m

Gross profit margin (Q3, 2020), %

26.9%

Net income (Q3, 2020)

(9.5m)

EBIT (Q3, 2020)

(9.7m)

Market capitalization (20-Jan-2021)

2.0b

Closing stock price (20-Jan-2021)

51.0

Cash (30-Sept-2020)

133.2m

EV

1.9b
Personalis's current market capitalization is $2 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

9.4m37.8m65.2m

Revenue growth, %

302%

Cost of goods sold

11.7m26.0m43.1m

Gross profit

(2.3m)11.8m22.1m
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

4.2m14.1m15.8m17.2m19.2m19.5m19.8m

Cost of goods sold

4.1m10.1m9.9m11.5m15.1m14.8m14.5m

Gross profit

99.0k4.0m5.9m5.6m4.0m4.7m5.3m

Gross profit Margin, %

2%28%37%33%21%24%27%
show all
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

22.6m19.7m55.0m

Accounts Receivable

1.9m4.5m3.3m

Prepaid Expenses

808.0k1.9m3.4m

Current Assets

26.7m29.6m139.6m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

33.2m163.3m87.0m46.7m25.0m133.2m

Accounts Receivable

3.1m7.5m4.4m5.5m5.4m5.9m

Prepaid Expenses

3.7m1.9m4.0m3.4m3.0m5.4m

Current Assets

42.9m176.2m140.3m135.4m120.1m223.6m
show all
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(23.6m)(19.9m)(25.1m)

Depreciation and Amortization

1.2m3.1m4.7m

Accounts Payable

2.6m2.2m1.4m

Cash From Operating Activities

290.0k5.6m(18.1m)
Quarterly
USDQ1, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(5.4m)(11.6m)(18.4m)(9.1m)(18.4m)(27.9m)

Depreciation and Amortization

471.0k2.2m3.4m1.4m2.8m4.3m

Accounts Payable

(732.0k)(163.0k)474.0k2.4m(348.0k)(1.6m)

Cash From Operating Activities

723.0k(10.8m)(20.5m)(8.6m)(24.0m)(40.1m)
show all
Show all financial metrics

Personalis Revenue Breakdown

Embed Graph

Personalis revenue breakdown by business segment: 50.8% from All other customers and 49.2% from VA MVP

Personalis Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

Learn more about our premium products
SecurityScorecard logo

Personalis Online and Social Media Presence

Personalis's Trends

Embed Graph

Personalis News and Updates

June 07, 2019

Cancer genomics company Personalis expects to raise up to $107 million in IPO

Personalis Inc. disclosed Friday terms of its initial public offering, in which the cancer genomics company could raise up to $106.7 million, and be valued at up to about $456 million. The company said it was offering 6,666,667 shares in the IPO, which is expected to price between $14 and $16 a sha…

Personalis Blogs

January 25, 2021

Specimen Preparation Guide for Clinical Use: FFPE

Specimen Preparation Guide for Clinical Use: FFPE To ensure submitted specimens yield sufficient amounts of extracted DNA and/or RNA for sequencing and analysis, we have provided the following guidelines below for solid tumors. Unacceptable specimens include hematolymphoid malignancies or decalcifi…
January 11, 2021

Personalis Reports Preliminary Fourth Quarter 2020 Revenue

Personalis Reports Preliminary Fourth Quarter 2020 Revenue pamleonardo Mon, 01/11/2021 - 16:02 Personalis Reports Preliminary Fourth Quarter 2020 Revenue January 11, 2021 This release is a backfill from a News Wire Earnings MENLO PAR…
January 07, 2021

Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy

Dan Brudzewsky, PhD Senior Field Applications Scientist - UK & Nordics Travis Yates, PhD Field Applications Scientist Tumor Mutational Burden: A Continually Evolving Biomarker for Immunotherapy Within recent years, the field of oncology has seen major advancements in regards to therapeutic…
December 28, 2020

Personalis to Present at the 23rd Annual Needham Virtual Growth Conference

MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 28, 2020-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021 at 2:45 p.m. Eastern Time .
December 17, 2020

Personalis Announces the Launch of NEOPS™, a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2020-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis’ state-of-the-art tumor neoantigen prediction
December 17, 2020

Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2020-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), the company’s proprietary, machine learning-based tool for the comprehensive
Show more

 Personalis Frequently Asked Questions

  • When was Personalis founded?

    Personalis was founded in 2011.

  • Who are Personalis key executives?

    Personalis's key executives are John West, Richard Chen and Aaron Tachibana.

  • How many employees does Personalis have?

    Personalis has 147 employees.

  • What is Personalis revenue?

    Latest Personalis annual revenue is $65.2 m.

  • What is Personalis revenue per employee?

    Latest Personalis revenue per employee is $443.6 k.

  • Who are Personalis competitors?

    Competitors of Personalis include NantOmics, SEASUN BIOMATERIALS and Prime Genomics.

  • Where is Personalis headquarters?

    Personalis headquarters is located at 1330 O'Brien Dr, Menlo Park.

  • Where are Personalis offices?

    Personalis has offices in Menlo Park and West Wickham.

  • How many offices does Personalis have?

    Personalis has 2 offices.